Open Interest and Volume Dynamics
On 8 September 2026, Divis Laboratories recorded an open interest (OI) of 74,089 contracts in its derivatives, marking a substantial increase of 9,549 contracts or 14.8% compared to the previous day’s OI of 64,540. This sharp rise in OI is accompanied by a trading volume of 1,20,079 contracts, indicating strong participation from traders and investors alike. The futures segment alone accounted for a value of approximately ₹65,467 lakhs, while the options segment’s notional value stood at an impressive ₹1,08,555 crores, culminating in a total derivatives value of ₹80,940 lakhs.
The underlying stock price has also been on an upward trajectory, hitting a new 52-week high of ₹9,532 during intraday trading. This price milestone was achieved alongside a narrow trading range of just ₹3.5, reflecting a controlled but confident buying interest. The stock opened with a gap-up of 2.33% and outperformed its sector by 1.85%, further underscoring its relative strength in the current market environment.
Market Positioning and Directional Bets
The surge in open interest, combined with rising volumes and price appreciation, typically signals fresh directional bets being placed by market participants. In Divis Laboratories’ case, the increase in OI alongside a rising price suggests that traders are predominantly taking long positions, anticipating further upside potential. This is corroborated by the stock’s consecutive gains over the past two sessions, delivering a cumulative return of 4.74% during this period.
Moreover, the stock is trading above all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — indicating a strong bullish trend across multiple timeframes. Such technical alignment often attracts momentum traders and institutional investors, reinforcing the positive sentiment.
Just made the cut! This Mid Cap from the Heavy Electrical Equipment sector entered our elite Top 1% list recently. Discover it before the crowd catches on!
- - Top-rated across platform
- - Strong price momentum
- - Near-term growth potential
Investor Participation and Liquidity Considerations
Despite the positive price and derivatives activity, investor participation in terms of delivery volumes has slightly declined. On 7 September 2026, the delivery volume was recorded at 3.23 lakh shares, down by 2.89% compared to the five-day average delivery volume. This suggests that while short-term trading interest is robust, longer-term holding interest may have moderated marginally.
Liquidity remains healthy, with the stock’s average traded value supporting trade sizes up to ₹8.58 crores based on 2% of the five-day average traded value. This level of liquidity is conducive for institutional investors and large traders to execute sizeable orders without significant market impact.
Mojo Score Upgrade Reflects Improving Fundamentals
MarketsMOJO has upgraded Divis Laboratories’ mojo grade from Hold to Buy as of 7 September 2026, reflecting improved fundamentals and technical outlook. The stock’s mojo score currently stands at 71.0, signalling a favourable risk-reward profile. As a large-cap pharmaceutical company with a market capitalisation of ₹2,48,319 crores, Divis Laboratories continues to command investor attention amid a sector that is witnessing steady growth and innovation.
Sector and Benchmark Comparison
On the day of the report, Divis Laboratories outperformed both its sector and the broader market benchmarks. The stock delivered a 1-day return of 2.42%, compared to the Pharmaceuticals & Biotechnology sector’s 0.44% gain and the Sensex’s decline of 0.55%. This relative outperformance highlights the stock’s resilience and appeal in a mixed market environment.
Want to dive deeper on Divis Laboratories Ltd? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Outlook and Investor Takeaways
The recent surge in open interest and volume in Divis Laboratories’ derivatives market, combined with its strong price performance and mojo upgrade, suggests that investors are positioning for continued upside in the near term. The stock’s technical strength across multiple moving averages and its ability to hit new 52-week highs reinforce this bullish outlook.
However, the slight dip in delivery volumes indicates that some investors may be adopting a cautious stance, possibly awaiting further confirmation of earnings or sector developments. Given the stock’s large-cap status and liquidity profile, it remains an attractive option for both momentum traders and long-term investors seeking exposure to the pharmaceuticals and biotechnology space.
In summary, Divis Laboratories is demonstrating robust market interest and positive sentiment, with derivatives activity signalling fresh directional bets favouring an upward trajectory. Investors should monitor open interest trends alongside price action and sector dynamics to gauge the sustainability of this momentum.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
